Back

Cancer Variant Interpretation Group UK (CanVIG-UK): updates on an exemplar national subspecialty multidisciplinary network

Garrett, A.; Allen, S.; Rowlands, C. F.; Choi, S.; Durkie, M.; Burghel, G. J.; Robinson, R.; Callaway, A.; Field, J.; Frugtniet, B.; Palmer-Smith, S.; Grant, J.; Pagan, J.; McDevitt, T.; Hughes, L.; Johnston, E.; Yarram-Smith, L.; Logan, P.; Reed, L.; Snape, K.; Hanson, H.; McVeigh, T. P.; Turnbull, C.; CanVIG,

2026-03-19 genetic and genomic medicine
10.64898/2026.03.17.26348157 medRxiv
Show abstract

Cancer Variant Interpretation Group UK was established in 2017 in response to the publication of the 2015 ACMG/AMP v3 guidance for the interpretation of sequence variants. Its initial purpose was to ensure consistency in the UK clinical-laboratory community implementation of ACMG/AMP v3 guidance for cancer susceptibility genes (CSGs). Still convening for monthly national meetings, the remit of CanVIG-UK now encompasses additional activities delivered under the following objectives: O_LICreation of a national multidisciplinary professional network and regular forum. C_LIO_LIDelivery of training and education. C_LIO_LIEstablishment of a consensus approach to the fundamentals of variant interpretation in cancer susceptibility genes. C_LIO_LIDevelopment and ratification of gene-specific frameworks for variant interpretation for cancer susceptibility genes. C_LIO_LIDevelopment and maintenance of an online platform to facilitate information sharing and variant interpretation within the UK clinical-laboratory community. C_LIO_LIFacilitation of UK contribution to international variant interpretation endeavours. C_LI A survey of CanVIG-UK members evaluating the impact of these activities conducted in November 2025 had 163 responses, including 113 clinical scientists/trainees and 27 Clinical Genetics consultants/trainees. The utility of the CanVIG-UK consensus recommendations for variant interpretation in cancer susceptibility genes was highly rated, with 89/145=61.4% of survey respondents reporting using the guidance at least weekly ([≥]4 times/month) and 124/128=96.9% rating it as extremely/very useful. The usage frequency and utility of the gene-specific guidance reported by survey respondents were similar to those reported for the main consensus specification. Both qualitative and quantitative survey responses clearly demonstrate the value of the CanVIG-UK activities to the clinical-diagnostic community. Key messagesO_LIWhat is already known on this topic: Cancer Variant Interpretation Group UK (CanVIG-UK) is a national subspeciality multidisciplinary network first established in 2017. It brings together members of the UK clinical-laboratory community to improve accuracy and consistency in the interpretation of variants in cancer susceptibility genes (CSG) C_LIO_LIWhat this study adds: this article presents the results of a survey of CanVIG-UK members, demonstrating the impact of CanVIG-UK activities on their services, as well as a review of progress in the six updated objectives of CanVIG-UK C_LIO_LIHow this study might affect research, practice or policy: this article presents current priorities and practices and potential future directions for variant interpretation in CSGs across the UK and Republic of Ireland C_LI

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
Genetics in Medicine
69 papers in training set
Top 0.1%
19.8%
2
Human Mutation
29 papers in training set
Top 0.1%
15.0%
3
European Journal of Human Genetics
49 papers in training set
Top 0.1%
14.6%
4
Genome Medicine
154 papers in training set
Top 0.7%
7.3%
50% of probability mass above
5
Journal of Medical Genetics
28 papers in training set
Top 0.1%
6.9%
6
BMJ Open
554 papers in training set
Top 9%
1.7%
7
Genes
126 papers in training set
Top 1%
1.7%
8
npj Genomic Medicine
33 papers in training set
Top 0.4%
1.7%
9
Frontiers in Molecular Biosciences
100 papers in training set
Top 2%
1.4%
10
Trials
25 papers in training set
Top 1%
1.4%
11
The Journal of Molecular Diagnostics
36 papers in training set
Top 0.3%
1.4%
12
The American Journal of Human Genetics
206 papers in training set
Top 3%
1.2%
13
Journal of Clinical Pathology
12 papers in training set
Top 0.3%
1.0%
14
Orphanet Journal of Rare Diseases
18 papers in training set
Top 0.5%
1.0%
15
PLOS ONE
4510 papers in training set
Top 64%
0.9%
16
F1000Research
79 papers in training set
Top 3%
0.9%
17
ERJ Open Research
44 papers in training set
Top 0.8%
0.8%
18
Nucleic Acids Research
1128 papers in training set
Top 17%
0.8%
19
BMC Medical Genomics
36 papers in training set
Top 1%
0.8%
20
BMC Genomics
328 papers in training set
Top 5%
0.8%
21
Human Genetics
25 papers in training set
Top 0.4%
0.8%
22
Frontiers in Genetics
197 papers in training set
Top 11%
0.7%
23
Journal of the American Medical Informatics Association
61 papers in training set
Top 2%
0.7%
24
Frontiers in Oncology
95 papers in training set
Top 4%
0.7%
25
Eurosurveillance
80 papers in training set
Top 2%
0.7%
26
Wellcome Open Research
57 papers in training set
Top 3%
0.7%
27
Frontiers in Bioinformatics
45 papers in training set
Top 1%
0.5%
28
Genomics
60 papers in training set
Top 4%
0.5%
29
GENETICS
189 papers in training set
Top 2%
0.5%
30
Archives of Disease in Childhood
15 papers in training set
Top 0.5%
0.5%